Iaso-003

Iaso-003 (also identified as Iaso-003+) is a monoclonal antibody (mAb) candidate currently in Phase 3 clinical development by Iaso Therapeutics. According to company pipeline documentation, the asset is being developed for 'future indications' leveraging the company's proprietary therapeutic platform. While specific biological targets and primary disease areas have not been publicly disclosed, the program represents a late-stage component of Iaso Therapeutics' portfolio, which centers on protein nanoparticle-based delivery and enhancement systems. The designation of 'future indications' suggests that the mAb may serve as a foundational or modular component of the company's broader platform-based therapeutic strategy.